Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®

Trial Profile

Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Aleglitazar (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms AleNEPHRO
  • Sponsors Roche
  • Most Recent Events

    • 25 Jun 2013 Results reporting lipid, glycaemic and insulin parameters presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
    • 11 Mar 2013 Results with focus on secondary endpoints presented at the 62nd Annual Scientific Session of the American College of Cardiology.
    • 05 Sep 2012 Primary endpoint 'Glomerular-filtration-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top